These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 13.01.2020, 20:18 and posted on 17.01.2020, 16:52by Oscar Méndez-Lucio, Paula Andrea Marin Zapata, Joerg Wichard, David Rouquié, Djork-Arné Clevert
Developing new small molecules that are bioactive is time-consuming, costly and rarely successful. As a mitigation strategy, we apply, for the first time, generative adversarial networks to de novo design of small molecules using a phenotype-based drug discovery approach. We trained our model on a set of 30,000 compounds and their respective morphological profiles extracted from high content images; no target information was used to train the model. Using this approach, we were able to automatically design agonist-like compounds of different molecular targets.